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Table 1. Summary of aGVHD severity and treatment response (N549)
Budesonide Single
Agent (N520)
Systemic
Corticosteroids (N525)
No Therapy or
Topical Steroids (N54)
Total
(N549)
N (%) Organs Involved
Skin Alone - 5 (20%) 3 (75%) 8 (16%)
GI Alone 9 (45%) 2 (8%) - 11 (23%)
Liver Alone - 1 (4%) 1 (25%) 2 (4%)
Skin/GI 9 (45%) 10 (40%) - 19 (39%)
GI/Liver 1 (5%) 3 (12%) - 4 (8%)
Skin/GI/Liver 1 (5%) 5 (20%) - 5 (10%)
N (%) Grade aGVHD
II 20 (100%) 5 (20%) 3 (75%) 28 (57%)
III - 15 (60%) 1 (25%) 16 (33%)
IV - 5 (20%) - 5 (10%)
N (%) Day 28 Treatment Response
CR/PR 7(35%)/9(45%) 8(32%)/12(48%) 3(75%)/1(25%) 40 (82%)
hPR 4 (20%) 5 (20%) - 9 (18%)
N (%) Day 56 Treatment Response
CR/PR 10(50%)/7(35%) 7(28%)/13(52%) 4 (100%)/ 0 41 (84%)
hPR 3 (15%) 5 (20%) - 8 (16%)
Poster Session II S343inhibitor and mycophenolate mofetil. Forty-nine patients developed
grade II-IV aGVHD by day 100 for a cumulative incidence of 50%
(95%CI:40-60) grade II-IV and 26% (95%CI:16-35) grade III-IV,
respectively. The median time of aGVHD onset was 39 days (range
14-99). Organs most commonly affected were skin/ GI (39%), GI
alone (23%), and skin alone (16%). Single agent budesonide was
used for the treatment of 20 patients with initial grade II GI aGVHD
(Table 1). Complete or partial responses (CR/PR) were observed by
day 28 in the majority (n5 16, 80%), which were maintained at day
56. Notably, only 3 of 20 budesonide patients required salvage with
systemic corticosteroids (2 responded, 1 progressed). Twenty-five
patients with predominantly grade III-IV aGVHD received systemic
corticosteroids from the outset of therapy (Table 1). CR or PR was
obtained in 80% by day 56. With a median follow-up of 24 months
(range 4.5-60.5), the 1-year cumulative incidence of ongoing late
acute or chronic GVHD was 35% (95%CI:26-45), and the 1-year
progression-free survival is 65% (95%CI:56-75). Seven patients
have died of GVHD, 2 patients initially treated with budesonide,
and 5 with systemic corticosteroids. We conclude that double unit
CBT is associated with a significant incidence of grade II-IV
aGVHDand new strategies for prophylaxis are warranted.However,
a significant number of patients with grade II GI aGVHD can be
treated successfully with budesonide alone, and this approach war-
rants prospective investigation. Finally, new therapies are needed
for CBT recipients with more severe aGVHD.530
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cGVHD is the most serious and common long-term complication
of this allogeneic transplantation, occurring in 30-70% of patients
surviving more than 100 days. cGVHD is associated with a high de-
gree of morbidity and mortality and remains a major cause of late
death. Initial therapy involves systemic corticosteroids which can
contribute to further complications. In cases where steroids are inef-
fective or poorly tolerated, effective therapeutic options are limited.
Anecdotal reports of myeloma patients treated with bortezomib after
transplantation have shown improvement in cGVHD.
We have begun a trial of bortezomib in patients with steroid-re-
fractory cGVHD. Patients receive 1.6 mg/m2 q wk x 4 followed by
one week of rest, for up to six cycles. To date 9 patients have beenentered on trial and 5 have completed between 2 and 4 cycles. The
treatment has been well tolerated with no grade 3 or higher adverse
events (AE). AE have been grade 1-2 nausea (3), grade 1-2 diarrhea
(6) grade 1-2 fatigue (4), one grade 2 transient neuropathy has
been reported. There have been 3 treatment delays (1 patient) and
dose reduction due to decreased hemoglobin and one due to tran-
sient neuropathy.
Subjective improvement has reported in 6 of the first 8 patients,
Improvement in general well-being has been noted as early as the
first treatment. Two patients have had improvement in severe long
standing sclerotic changes, including the ability to extend fingers
that had long been contracted. Average Rodnan scores on 5 patients
with sclerosis completing 2 or more cycles of therapy decreased from
(3169.6 to 13.867.5) One patient with non-healing suppurating le-
sions of his lower extremities has shownmarked healing, another has
significant decrease in chronic diarrhea.
Weekly bortezomib for cGVHD appears to be well tolerated and
results in early improvement in long standing refractory disease. Our
plan is to enroll twenty-five patients to determine if these encourag-
ing findings are sustainable.531
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Background: The great variability in the diagnosis of chronic
GVHD and the long period required to complete clinical trials
